Barclays raised the firm’s price target on Bristol Myers to $43 from $42 and keeps an Underweight rating on the shares as part of an earnings preview for the biopharmaceutical group. The firm sees a challenging large-cap biopharma setup for Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Trump backs off support of controversial drug pricing plan, STAT reports
- Bristol Myers announces FDA approval of Opdivo for treatment of NSCLC
- Stellantis cuts 2024 targets, TPG acquires AT&T’s DirecTV stake: Morning Buzz
- Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley
- Prime Medicine pact with Bristol doesn’t change thesis, says Stifel